Clinical Trial Update: Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and efficacy of PTC124 (ataluren) in Duchenne muscular dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PTC124 (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED